Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 4/20 | 0.39 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.38 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 3/20 | 0.37 |
| ▸ | APLNR | P35414 | 1/20 | 0.37 |
| ▸ | SCD | O00767 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | METAP1 | P53582 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14116755 | 0.83 | CYP17A1 (0.42) | CYP17A1ATRPCSK9PSMB8NAMPT | |
| SCHEMBL32683223 | 0.80 | L3MBTL1 (0.44) | CYP17A1ATRL3MBTL1PCSK9PSMB8 | |
| SCHEMBL17844767 | 0.80 | KMT2A (0.49) | CYP17A1ATRPSMB8NAMPTGSK3B | |
| SCHEMBL29168119 | 0.78 | KMT2A (0.42) | L3MBTL1PCSK9 | |
| SCHEMBL29168120 | 0.78 | KMT2A (0.42) | L3MBTL1PCSK9 | |
| SCHEMBL14116754 | 0.78 | ATR (0.43) | CYP17A1ATRPCSK9PSMB8NAMPT | |
| SCHEMBL6292251 | 0.78 | CYP17A1 (0.40) | CYP17A1ATRPCSK9PSMB8NAMPT | |
| SCHEMBL19373777 | 0.76 | CYP17A1 (0.40) | CYP17A1ATRPCSK9PSMB8NAMPT | |
| SCHEMBL23371285 | 0.76 | PCSK9 (0.41) | PCSK9RORCAPLNRCA12CA1 | |
| SCHEMBL29168312 | 0.76 | LMNA (0.40) | PCSK9CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107074874-B | ERK inhibitor | 伊莱利利公司 | 2019-04-23 | — | — | CN | disclosed |
| EP-3237420-B1 | ERK INHIBITORS | LILLY CO ELI (US) | 2018-09-26 | — | — | EP | disclosed |
| US-9879029-B2 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2018-01-30 | — | — | US | disclosed |
| US-9879029-B2 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2018-01-30 | — | — | US | disclosed |
| US-9879029-B2 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2018-01-30 | — | — | US | disclosed |
| EP-3237420-A1 | ERK INHIBITORS | Eli Lilly and Company (US) | 2017-11-01 | — | — | EP | disclosed |
| US-20170267691-A1 | ERK INHIBITORS | LILLY CO ELI (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170267691-A1 | ERK INHIBITORS | LILLY CO ELI (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170267691-A1 | ERK INHIBITORS | LILLY CO ELI (US) | 2017-09-21 | — | — | US | disclosed |
| CN-107074874-A | Erk inhibitor | 伊莱利利公司 | 2017-08-18 | — | — | CN | disclosed |
| WO-2016106009-A1 | ERK INHIBITORS | ELI LILLY AND COMPANY (US) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267691-A1 | ERK INHIBITORS | MAPK4, MAPK1, MAPK3 | CYP17A1 3776/4885ATR 1138/4885L3MBTL1 2333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.